1st Aug 2014 05:56
LONDON (Alliance News) - GlaxoSmithKline PLC and Genmab A/S said late Thursday that at an independent data monitoring committee interim analysis of its phase III study of ofatumumab showed that it had met its primary endpoint of improving progressing free survival.
The study evaluated maintenance therapy with the treatment against no further treatment in patients with chronic lymphocytic leukaemia who responded to treatment at relapse.
The committee did not identify any new safety signals, Glaxo said, and will continue to monitor patients for safety until all of the patients in the study complete therapy.
"We look forward to sharing the results of the interim analysis with regulatory agencies to evaluate the potential for future regulatory filings," said Glaxo's Head of Oncology Research and Development Rafael Amado in a statement.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline